Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.49 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.47 |
| ▸ | ACACB | O00763 | 3/20 | 0.46 |
| ▸ | ACACA | Q13085 | 3/20 | 0.46 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4996485 | 0.94 | HSP90AB1 (0.52) | HSP90AB1KDM4EPOLBALDH1A1KDM2B | |
| SCHEMBL4977942 | 0.92 | KDM4E (0.53) | HSP90AB1KDM4EPOLBALDH1A1KDM2B | |
| SCHEMBL4976026 | 0.92 | HRH3 (0.54) | HSP90AB1KDM4EPOLBALDH1A1KDM2B | |
| SCHEMBL4975336 | 0.90 | HSP90AB1 (0.49) | HSP90AB1KDM4EALDH1A1HRH3 | |
| SCHEMBL4979058 | 0.90 | KDM2B (0.53) | HSP90AB1POLBKDM2BHRH3L3MBTL3 | |
| SCHEMBL4977103 | 0.90 | HSP90AB1 (0.63) | HSP90AB1KDM4EALDH1A1HRH3L3MBTL3 | |
| SCHEMBL4978554 | 0.90 | HSP90AB1 (0.63) | HSP90AB1KDM2BHRH3L3MBTL3L3MBTL1 | |
| SCHEMBL4978632 | 0.90 | HSP90AB1 (0.51) | HSP90AB1KDM4EKDM2BHRH3L3MBTL3 | |
| SCHEMBL4974931 | 0.89 | HSP90AB1 (0.48) | HSP90AB1POLBALDH1A1HRH3L3MBTL3 | |
| SCHEMBL4976040 | 0.89 | HRH3 (0.54) | KDM2BHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080051387-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES | NEUROGEN CORPORATION | 2008-02-28 | — | — | US | disclosed |
| US-20080051387-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES | NEUROGEN CORPORATION | 2008-02-28 | — | — | US | disclosed |
| US-20080051387-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES | NEUROGEN CORPORATION | 2008-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051387-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES | HRH3, HRH4, HRH2 | HSP90AB1 2652/4885KDM4E 1865/4885POLB 1658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.